

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM697636

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
VYNE Therapeutics Inc.		11/04/2021	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	VYNE Pharmaceuticals Inc.		
Street Address:	520 U.S. Highway 22		
Internal Address:	Suite 204		
City:	Bridgewater		
State/Country:	NEW JERSEY		
Postal Code:	08807		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 9			
Property Type	Number	Word Mark	
Serial Number:	88308081	MST	
Serial Number:	90892398	MST	
Registration Number:	6024563	AMZEEQ	
Registration Number:	6034820		
Registration Number:	6034819	AMZEEQ	
Registration Number:	6505432		
Registration Number:	6235231	ZILXI	
Registration Number:	6223436		
Registration Number:	6223434		
CORRESPONDENCE DATA			
Fax Number:	2024084400		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	202-408-4000		
Email:	docketing@finnegan.com		
Correspondent Name:	Christie Baty Hudgins		
Address Line 1:	901 New York Avenue NW		
Address Line 2:	Finnegan, Henderson, Farabow et al.		
Address Line 4:	Washington, D.C. 20001		

OP \$240.00 88308081

ATTORNEY DOCKET NUMBER:	13949.3048
NAME OF SUBMITTER:	Christie Baty Hudgins
SIGNATURE:	/Christie Baty Hudgins/
DATE SIGNED:	12/26/2021

Total Attachments: 5

source=assignment VTI to VPI - eff 11-4-21 __Redacted__#page1.tif

source=assignment VTI to VPI - eff 11-4-21 __Redacted__#page2.tif

source=assignment VTI to VPI - eff 11-4-21 __Redacted__#page3.tif

source=assignment VTI to VPI - eff 11-4-21 __Redacted__#page4.tif

source=assignment VTI to VPI - eff 11-4-21 __Redacted__#page5.tif

TRADEMARK ASSIGNMENT AGREEMENT

WHEREAS, VYNE Therapeutics Inc., a Delaware corporation with an address at 520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey, 08807 ("Assignor"), is the record owner of the trademarks and service marks identified on Schedule A and of the registrations and applications therefor ("the Trademarks"); and

WHEREAS, on the Effective Date, VYNE Pharmaceuticals Inc., a Delaware corporation with an address at 520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey, 08807 ("Assignee"), is desirous of securing the entire right, title, and interest in all countries throughout the world in and to the Trademarks and the Assignor is ready, willing and able to assign to the Assignee all such right, title and interest.

NOW THEREFORE, be it known that as of the Effective Date and in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby assign to Assignee, as a contribution to capital of the Assignee intended to qualify for tax-free treatment under section 351 of the Internal Revenue Code of 1986, and the Assignee hereby accepts all of its right, title, and interest in and to the Trademarks (including any common law rights thereto), together with the goodwill of the business associated with and symbolized by the Trademarks, and the right to sue and recover for past or future infringement, dilution, and other violation thereof and the Assignee accepts responsibility for all the costs and expenses involved in and incidental to recording and perfecting the assignment referred to herein;

AND, ASSIGNOR HEREBY authorizes and requests the Commissioner of Patents and Trademarks in the United States and any official of any foreign country whose duty it is to register trademarks to record the transfer of the Trademarks to Assignee, its successors and assigns, as recipient of the Assignor's entire right, title, and interest therein in accordance with the terms of this Assignment;

AND, ASSIGNOR AND ASSIGNEE HEREBY further covenant and agree that duplicate assignments may be drawn up for each country or jurisdiction in accordance with local practice listing just the trademarks and trademark applications for that country or jurisdiction to facilitate recordation in each country or jurisdiction;

AND, ASSIGNEE HEREBY accepts this transfer and assignment. The legal transfer and assignment under this Assignment is effective as of November 4, 2021 (the "Effective Date").

IN WITNESS WHEREOF, ASSIGNOR has executed this Assignment by its duly authorized representative.

Name: VYNE Therapeutics Inc.

Address: 520 U.S. Highway 22
Suite 204
Bridgewater, NJ 08807
U.S.A.

By: 

Name: David Domzalski

Title: Chief Executive Officer

Date: November 4, 2021

ACKNOWLEDGED BY:

Name: VYNE Pharmaceuticals Inc.

Address: 520 U.S. Highway 22
Suite 204
Bridgewater, NJ 08807
U.S.A.


By: 

Name: Tyler Zeranda

Title: Chief Financial Officer






Date: November 4, 2021

Schedule A




UNITED STATES

Registered Trademarks

Mark	Class	Registration No.	Registration Date
AMZEEQ	5	6024563	3/31/2020
Drop Logo 	5	6034820	4/14/2020
AMZEEQ and Drop Logo 	5	6034819	4/14/2020
Fingerprint design 	5	6505432	10/5/2021
ZILXI	5	6235231	12/29/2020
PEBBLE Logo 	5	6223436	12/15/2020
PEBBLE Logo Color 	5	6223434	12/15/2020

Pending Applications

Mark	Class	Application No.	Application Date
MST	3 and 5	88308081	2/20/2019
MST Logo 	5	90892398	8/19/2021

CONFIDENTIAL